There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adaptimmune Therapeutics (ADAP – Research ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

The "Refractory Metastatic Melanoma - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 4+ companies and 4+ ...

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

BioNTech is expanding its oncology pipeline with FixVac, iNeST, and BNT327 for individualized cancer treatments. Read why I ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...

Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...